NUVO

[kslifka]

Watching NUVO.  In fact it appears many of the beaten down "bio-techs" of the summer are showing signs of Life.  (I can't believe I missed AGIX yesterday.  I looked at it the night before )

If NUVO can get above $2.10 and hold it.  I believe NUVO can go much higher.  But just watching right now...and I will pull the trigger today if it happens.

NUVO came back to life after this news:

Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
Wednesday August 22, 6:30 am ET
- Revised Trial Examines Single, Higher, More Concentrated Dose of Alfimeprase -

SAN CARLOS, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO - News) today announced enrollment of the first patient in the SONOMA-3 (Speedy Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase-3) trial evaluating lead product candidate, alfimeprase, for the treatment of central venous catheter occlusion (CO).

ADVERTISEMENT
This open-label, single-arm trial will evaluate the safety and efficacy of a single 10 milligram dose of alfimeprase with a concentration of 5 milligrams per milliliter in up to 100 patients with occluded central venous catheters.

Data from a previous Phase 3 trial in the CO program, SONOMA-2, showed that alfimeprase restored catheter function in patients with occluded catheters within 15 minutes with a p-value of 0.022. It did not however, meet the more stringent p-value required for a single pivotal trial, less than 0.00125.

"Analysis of data from our previous Phase 3 SONOMA study provided further evidence that alfimeprase is an active thrombolytic which has the potential to dissolve clots quickly and rapidly restore catheter function, however, the dose and concentration we used did not generate results in line with the target product profile we believe necessary for commercial success in this market," said Michael Levy, M.D., executive vice president of research and development for Nuvelo. "Preclinical experiments have provided evidence that increasing the concentration can result in marked improvement in thrombolytic activity. Accordingly, we are resuming development of alfimeprase in CO to evaluate the potential of a single, higher, more concentrated dose and expect data from this trial in 2008."

[kslifka]

o.k.  Jumped in at 2.10...after breakout

If volume doesn't kick in I'll sell...hopefully around the 50dma.

[Holygrale]

Not a bad looking chart..........

UBS upgrade on Nov 29th........

[Holygrale]

Close at High of Day........

3 month average volume is 500,000.

Hopefully this action continues, it's having good volume ....

4-Dec-07   1.84 2.06 1.84 2.05      1,705,500
3-Dec-07   1.77 1.93 1.74 1.87      747,700
30-Nov-07 1.84 1.85 1.67 1.74      1,309,400
29-Nov-07 1.73 1.96 1.68 1.79      2,227,000
28-Nov-07 1.30 1.58 1.28 1.52      1,206,200

[Holygrale]

Shes got legs.......


Nice!